Advanced Oncotherapy (AVO) goal is to deliver an affordable and novel proton beam therapy system (PBT), based on state-of-the-art technology developed originally at the world-renowned CERN. 2018 was characterised by the achievement of a number of technical milestones, the successful integration of all the module types that constitute the LIGHT accelerator, and the acceleration of the proton beam to an energy of 52MeV, sufficient to treat superficial tumours. Meanwhile, AVO has started to gear up its commercial infrastructure through the recruitment of a Chief Commercial Officer (CCO) with experience in PBT solutions.

► Strategy: AVO is developing a compact and modular PT system at an affordable price for the payor, financially attractive to the operator, and generating superior patient outcomes. AVO benefits from the technology know-how developed by ADAM, Geneva, and relies on a base of world-class suppliers.

► Senior management appointment: In preparation for the commercialisation of LIGHT, AVO has appointed Moataz Karmalawy as CCO, and President for its US operations. Previously, he was General Manager worldwide for Particle Therapy Treatment at Varian Medical, a global leader and ranked #2 in PBT.

► Rationale: Given his experience at Varian, and Philips Medical, Moataz will provide AVO with a wealth of knowledge in the commercialisation of PBT solutions. This appointment is a major coup for AVO and provides a considerable vote of confidence in LIGHT’s attractive proposition.

► Risks: In 2018, the more complex technical challenges were overcome and progress towards a fully functional accelerator is underway in preparation for CE marking. Execution risk remains; however, establishment of an innovative financing package for providing LIGHT to potential customers has lowered this risk.

► Investment summary: Demand for PBT is increasing worldwide, and the need for a small, flexible, affordable and close-to-patient system is desirable. With LIGHT, AVO is aiming to provide customers with a fully integrated PBT solution. AVO’s market capitalisation of £78m equates only to the amount of money invested into LIGHT to date, which does not reflect either the enormous technical challenges that have been overcome, or the large market potential.

### Financial summary and valuation

<table>
<thead>
<tr>
<th>Year end Dec (Em)</th>
<th>2015</th>
<th>2016</th>
<th>2017</th>
<th>2018E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Gross profit</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Administration costs</td>
<td>-6.6</td>
<td>-11.2</td>
<td>-12.9</td>
<td>-14.0</td>
</tr>
<tr>
<td>EBITDA</td>
<td>-6.4</td>
<td>-10.8</td>
<td>-12.6</td>
<td>-13.6</td>
</tr>
<tr>
<td>Underlying EBIT</td>
<td>-6.6</td>
<td>-11.2</td>
<td>-12.9</td>
<td>-14.0</td>
</tr>
<tr>
<td>Statutory EBIT</td>
<td>-8.5</td>
<td>-13.1</td>
<td>-14.5</td>
<td>-17.0</td>
</tr>
<tr>
<td>Underlying PTP</td>
<td>-6.7</td>
<td>-11.3</td>
<td>-14.9</td>
<td>-14.3</td>
</tr>
<tr>
<td>Statutory PTP</td>
<td>-8.6</td>
<td>-13.2</td>
<td>-15.6</td>
<td>-17.3</td>
</tr>
<tr>
<td>Underlying EPS (p)</td>
<td>-7.1</td>
<td>-13.9</td>
<td>-15.6</td>
<td>-7.6</td>
</tr>
<tr>
<td>Statutory EPS (p)</td>
<td>-12.3</td>
<td>-14.3</td>
<td>-18.9</td>
<td>-9.7</td>
</tr>
<tr>
<td>Net (debt)/cash</td>
<td>8.0</td>
<td>9.2</td>
<td>7.3</td>
<td>0.7</td>
</tr>
<tr>
<td>Capital increase</td>
<td>21.1</td>
<td>13.5</td>
<td>7.3</td>
<td>20.5</td>
</tr>
</tbody>
</table>

Source: Hardman & Co Life Sciences Research

Disclaimer: Attention of readers is drawn to important disclaimers printed at the end of this document.
Gearing up for commercialisation

AVO is aiming, with LIGHT, to deliver not only the next-generation proton accelerating system but also a solution that addresses most of the challenges in the PBT market. Having overcome many of the technical challenges in 2018, AVO is now focusing increasingly on the commercialisation of its fully integrated PBT system.

Senior management appointment

Today, AVO has strengthened its senior management team with the appointment of Moataz Karmalawy – a veteran in the commercialisation of PBT technology – as its CCO and President for the US operations, with immediate effect. This move is a clear signal that AVO is preparing its commercial infrastructure for LIGHT. In our opinion, the appointment of such an experienced executive from a major competitor is a major coup for the company and should provide the market with greater confidence in LIGHT’s commercial prospects.

Moataz Karmalawy

Prior to joining AVO, Moataz was the General Manager for Worldwide Particle Therapy Treatment at Varian Medical Systems (Varian). Prior to that, he spent 10 years at Philips Medical Systems (Philips) in the US.

During his 12 years at Varian, Moataz was responsible for all aspects of the company’s PBT business worldwide, such as P&L, operations, services, R&D, marketing, sales, finance, and site solutions. When Varian acquired its PBT business, Moataz was central to the integration of the business into the organisation. Subsequent to this, he was a key figure in developing the commercial aspect of Varian’s PBT business from $10m to $150m in 2018 with a strong order book. At Varian, his main achievements included:

► development and execution strategy for global sales & marketing covering three-tier plans – market penetration, dominance and expansion in five years;
► achievement of 50% global market share for Particle Therapy Products;
► negotiating large complex customer deals, each averaging $50m worldwide;
► developing a public-tender response and contract development team, which successfully addressed needs in APAC and Europe;
► establishment of strategic partnerships with leading financial institutions and medical centres for successful market growth; and
► increasing reimbursement codes and developing new code with Centers for Medicare & Medicaid Services (CMS).

At Philips, Moataz held a variety of management positions, including VP for Research and Development, VP of Operations, and VP of strategic R&D. Prior to that, he spent five years directing Nuclear Medicine Systems operations at Park Medical Systems in Canada. Moataz holds an M.A.Sc. and a Ph.D. in Engineering, as well as an MBA from Concordia University and McGill University in Montreal, Canada. He also holds a number of patents and has published in major technical journals.

Recruitment of an experienced, high-profile executive from a major industry competitor indicates that LIGHT is an attractive proposition that is providing a disruptive solution in a market which has high medical need. It is also an acknowledgement that much of the technical risk is under control and the focus of the company is being switched from development to commercial activity. This move also expands AVO’s geographical reach to the US from its existing base in Europe, and Asia, through its partnership with Yantai CIPU.
Varian Medical Systems

Varian is an established and leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, stereotactic radiosurgery, stereotactic body radiotherapy, brachytherapy and proton therapy. Its stated mission is to combine the ingenuity of people with the power of data and technology to achieve better clinical outcomes in the fight against cancer. In PBT, Varian currently has 28 rooms in operation, ranking it the #2 manufacturer of proton therapy solutions, and a strong order book of ca.30 rooms.

Varian has two reportable operating segments:

► **Oncology Systems:** Designs, manufactures, sells and services hardware (such as linear accelerator) and software products for treating cancer with conventional radiotherapy, and advanced treatments.

► **Proton Solutions:** Develops, designs, manufactures, sells and services products and systems for delivering proton beam therapy.

Development update

Moataz is joining AVO at an exciting time. During 2018, the company made enormous progress and hit a number of technical milestones that greatly de-risked the whole project. LIGHT has reached the stage where the four different modules (the proton source, the RFQ, the SCDTLs and the CCLs) that constitute the accelerator have been integrated at its Geneva testing site and the proton beam has been accelerated to an energy level of 52MeV, which would be sufficient to treat superficial tumours. While specific testing is still being undertaken, on a broader front, sufficient testing has taken place to show proof-of-concept. The company will undertake a number of actions during 2019 to generate the first complete LIGHT system, which will be used to obtain regulatory approval, via CE marking.

Daresbury site

In May 2018, a lease was signed between AVO and the UK Government’s Science and Technology Facilities Council (STFC) to establish a UK testing and assembly site at Daresbury (Cheshire). The facility will be used to test and assemble a complete and operational version of the LIGHT system for verification and validation for regulatory approval (CE marking). The infrastructure work has already started, together with assembly of the LIGHT system, as both are meant to be built in parallel. The concrete shielding for the proton injector and RF test bunkers is already in place, and delivery of the components has already happened.

CE marking

AVO is in regular discussions with its Notified Body. On completion of the verification and validation of the LIGHT system, AVO expects to receive CE marking from the Medical and Healthcare products Regulatory Agency (MHRA). Important within this process was the third-party ISO 13485 certification, which demonstrated to the regulators that AVO has met the stringent requirements of the standard. We expect AVO to have all the accelerating structures of LIGHT integrated before the end of 2019, with submission for CE marking happening shortly thereafter. This system will then be dismantled for re-construction at the Harley Street site, with the first patients expected to be treated by the end of 2020.
Disclaimer

Hardman & Co provides professional independent research services and all information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. However, no guarantee, warranty or representation express or implied, can be given by Hardman & Co as to the accuracy, adequacy or completeness of the information contained in this research and they are not responsible for any omissions or results obtained from use of such information. Neither Hardman & Co, nor any affiliates, officers, directors or employees accept any liability or responsibility in respect of the information which is subject to change without notice and may only be correct at the stated date of their issue, except in the case of gross negligence, fraud or wilful misconduct. In no event will Hardman & Co, its affiliates or any such parties be liable to you for any direct, special, indirect, consequential, incidental damages or any other damages of any kind even if Hardman & Co has been advised of the possibility thereof.

This research has been prepared purely for information purposes, and nothing in this report should be construed as an offer, or the solicitation of an offer, to buy or sell any security, product, service or investment. The research reflects the objective views of the analyst(s) named on the front page and does not constitute investment advice. However, the companies or legal entities covered in this research may pay us a fixed fee in order for this research to be made available. A full list of companies or legal entities that have paid us for coverage within the past 12 months can be viewed at http://www.hardmanandco.com/legalresearchdisclosures. Hardman may provide other investment banking services to the companies or legal entities mentioned in this report.

Hardman & Co has a personal dealing policy which restricts staff and consultants’ dealing in shares, bonds or other related instruments of companies or legal entities which pay Hardman & Co for any services, including research. No Hardman & Co staff, consultants or officers are employed or engaged by the companies or legal entities covered by this document in any capacity other than through Hardman & Co.

Hardman & Co does not buy or sell shares, either for their own account or for other parties and neither do they undertake investment business. We may provide investment banking services to corporate clients. Hardman & Co does not make recommendations. Accordingly, they do not publish records of their past recommendations. Where a Fair Value price is given in a research note, such as a DCF or peer comparison, this is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. Hardman & Co may publish further notes on these securities, companies and legal entities but has no scheduled commitment and may cease to follow these securities, companies and legal entities without notice.

The information provided in this document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject Hardman & Co or its affiliates to any registration requirement within such jurisdiction or country.

Some or all alternative investments may not be suitable for certain investors. Investments in small and mid-cap corporations and foreign entities are speculative and involve a high degree of risk. An investor could lose all or a substantial amount of his or her investment. Investments may be leveraged and performance may be volatile; they may have high fees and expenses that reduce returns. Securities or legal entities mentioned in this document may not be suitable or appropriate for all investors. Where this document refers to a particular tax treatment, the tax treatment will depend on each investor’s particular circumstances and may be subject to future change. Each investor’s particular needs, investment objectives and financial situation were not taken into account in the preparation of this document and the material contained herein. Each investor must make his or her own independent decisions and obtain their own independent advice regarding any information, projects, securities, tax treatment or financial instruments mentioned herein. The fact that Hardman & Co has made available through this document various information constitutes neither a recommendation to enter into a particular transaction nor a representation that any financial instrument is suitable or appropriate for you. Each investor should consider whether an investment strategy of the purchase or sale of any product or security is appropriate for them in the light of their investment needs, objectives and financial circumstances.

This document constitutes a ‘financial promotion’ for the purposes of section 21 Financial Services and Markets Act 2000 (United Kingdom) (FSMA) and accordingly has been approved by Capital Markets Strategy Ltd which is authorised and regulated by the Financial Conduct Authority (FCA).

No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any means, mechanical, photocopying, recording or otherwise, without prior permission from Hardman & Co. By accepting this document, the recipient agrees to be bound by the limitations set out in this notice. This notice shall be governed and construed in accordance with English law. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the FCA under registration number 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

(Disclaimer Version 8 – Effective from August 2018)